

Anthony M. Casapao, Pharm.D.

University of Florida College of Pharmacy
580 W. 8th Street
Jacksonville, FL 32209
(904) 244-9129
casapao@cop.ufl.edu

Residential Address
PO Box 550552
Jacksonville, FL 32255
(847) 271-1100
casapao@mail.harvard.edu

Education

Master in Public Health concentration in Epidemiology and Biostatistics Harvard University School of Public Health – Boston, Massachusetts	2016 – Present
Doctor of Pharmacy, <i>Cum Laude</i> Wingate University School of Pharmacy – Wingate, North Carolina	2005 – 2009
Bachelor of Science in Biomedical Science, <i>Magna Cum Laude</i> Midwestern University – Glendale, Arizona	2003 – 2005
Associate in Science College of Lake County – Grayslake, Illinois	2000 – 2003

Professional Experience

<i>Clinical Assistant Professor of Pharmacotherapy and Translational Research</i> University of Florida College of Pharmacy – Jacksonville, FL	Oct 2017– Present
<i>Assistant Professor of Pharmacy Practice</i> Husson University School of Pharmacy – Bangor, ME	April 2014 – October 2017
<i>Pharmacotherapy Infectious Diseases Outcomes Research</i> Fellowship Program (ACCP Peer Reviewed) Wayne State University – Detroit, MI Fellowship Directors: Michael J. Rybak, Pharm.D., MPH, FCCP & Susan L. Davis, Pharm.D.	August 2011– March 2014
<i>Post Graduate Year-2 Infectious Diseases</i> Residency Program (ASHP-Accredited) University of Pittsburgh Medical Center – Pittsburgh, PA Residency Director: Brian A. Potoski, Pharm.D., BCPS AQ-ID	July 2010 – July 2011
<i>Post Graduate Year-1 Pharmacy Practice</i> Residency Program (ASHP-Accredited) St. Vincent’s Medical Center – Jacksonville, FL Residency Director: Michele Loudy, Pharm.D., BCPS	June 2009 – July 2010
<i>Adjunct Instructor</i> Wayne State University Eugene Applebaum College of Pharmacy and Health Sciences Mentor: Michael J. Rybak, Pharm.D., MPH, FCCP	August 2011– Present
<i>Adjunct Instructor Teaching Certificate</i>	September 2010 – June 2011

University of Pittsburgh School of Pharmacy – Pittsburgh, PA
 Program Director: Denise L. Howrie, Pharm.D.

Adjunct Instructor Teaching Certificate July 2009 – July 2010
 University of Florida College of Pharmacy – Jacksonville, FL
 Program Director: Lisa D. Inge, Pharm.D., BCPS, AAHIVE

Pharmacy Intern Summer 2007
 Harris Teeter Store #129 – Indian Trail, North Carolina
 Pharmacy Manager: Kevin Pultorak, R.Ph.

Pharmacy Technician 2001 – 2003
 Highland Park Hospital, an Evanston Northwestern Hospital – Highland Park, IL
 Pharmacy Director: Mike Sura, Pharm.D.

Pharmacy Technician 2000 – 2002
 Walgreen’s Pharmacy – Libertyville, Illinois
 Pharmacy Manager: Lowell Sederstrom, R.Ph.

Clinical Experience

Clinical Infectious Diseases Pharmacotherapy Specialist September 2014 – October 2017
 Antimicrobial Stewardship Committee and Infection Prevention and Control Function Team
 Department of Pharmacy, Eastern Maine Medical Center, Bangor, Maine

HAI Collaborating Partners Committee: Pharmacy Member July 2015 – October 2017
 Maine Center for Disease Control and Prevention, Augusta, Maine

Rotation	Preceptor	Duration
Infectious Diseases Pharmacotherapy Research Outcomes Fellowship		
Infectious Diseases Consult	Michael J. Rybak, Pharm.D., MPH	30 weeks
PGY-2 Infectious Diseases Pharmacotherapy Residency		
Infectious Diseases Consult	Brian A. Potoski, Pharm.D., BCPS AQ-ID	32 weeks
Antibiotic Stewardship	Greg Eschenauer, Pharm.D., BCPS	4 weeks
Clinical Microbiology	A. William Pasculle, Sc.D.	8 weeks
Research Microbiology	Yohei Doi, MD, PhD	8 weeks
Antibiotic Management	Greg Eschenauer, Pharm.D., BCPS	Longitudinal
PGY-1 Pharmacy Practice Residency		
Critical Care & ID	Yasi Homayouni, Pharm.D.	4 weeks
Quality Management	Charzetta James, Pharm.D., MBA	4 weeks
Emergency Medicine	Sarah Hayes, Pharm.D.	4 weeks
Pharmacy Management	Karen Rehmer, R.Ph.	Longitudinal
Pharmacy Operations	Karen Rehmer, R.Ph.	4 weeks
Pharmacy Management	Adam N. Bauman, M.S., R.Ph.	4 weeks
Family Medicine	Michele Loudy, Pharm.D., BCPS	4 weeks
Quality Management	Charzetta James, Pharm.D., MBA	Longitudinal
Oncology	Robin Bettman, R.Ph., BCOP	4 weeks
Internal Medicine II	Michele Loudy, Pharm.D., BCPS	4 weeks
PGY-1 Pharmacy Practice Residency cont.		

Infectious Diseases	Kevin Epps, Pharm.D.	4 weeks
Formulary Management	Lauren Stafford, Pharm.D., BCPS	Longitudinal
Drug Information	Lauren Stafford, Pharm.D., BCPS	4 weeks
Critical Care	John Totty Johnson, R.Ph.	4 weeks
Internal Medicine	Victoria Evelyn, Pharm.D.	4 weeks
Pharmacy Administration	Adam N. Bauman, M.S., R.Ph.	Longitudinal

Peer-Reviewed Publications

Jacobs DM, Dilworth TJ, Beyda NE, **Casapao AM**, Bowers DR. Overtreatment of Asymptomatic Candiduria among Hospitalized Patients: A Multi-institutional Study. *Submitted to Antimicrob Agents Chemother* on October 13th and under peer review.

Casapao AM, Jacobs DM, Bowers DR, Beyda NE, Dilworth TJ. Early Administration of Adjuvant β -lactam Therapy in Combination with Vancomycin among Patients with Methicillin-Resistant *Staphylococcus aureus* Bloodstream Infection: A Retrospective, Multicenter Analysis. *Pharmacotherapy*. 2017 Sept 26 [Epub ahead of print].

Zasowski EJ, Trinh TD, Claeys KC, **Casapao AM**, Sabagha N, Lagnf AM, Klinker KP, Davis SL, Rybak MJ. A Multicenter Observational Study of Ceftaroline Fosamil for Methicillin-Resistant *Staphylococcus aureus* Bloodstream Infections. *Antimicrob Agents Chemother*. 2017 Jan;61(2). pii:e0215-16.

Bosso JA, **Casapao AM**, Edwards J, Klinker K, McCoy C, Nicolau DP, Perez KK, Marcarelli A, Dua D. Clinical pathway for moderate to severe acute bacterial skin and skin structure infections from a US perspective: a roundtable discussion. *Hosp Pract (1995)*. 2016 Oct;44(4):183-189.

Claeys KC, Zasowski EJ, **Casapao AM**, Lagnf AM, Nagel JL, Nguyen CT, Hallesy J, Compton MT, Kaye KS, Levine DP, Davis SL, Rybak MJ. Daptomycin Improves Outcomes Regardless of Vancomycin MIC in a Propensity-Matched Analysis of Methicillin-Resistant *Staphylococcus aureus* Bloodstream Infections. *Antimicrob Agents Chemother*. 2016 Sep 23;60(10):5841-8.

Lagnf AM, **Casapao AM**, Claeys KC, Rybak MJ. Comparison of Clinical Outcomes and Risk Factors in Polymicrobial versus Monomicrobial Enterococcal Bloodstream Infections. *Am J Infect Control* 2016; Aug;44(8):917-21.

Casapao AM, Lodise TP, Davis SL, Claeys KC, Kullar R, Levine DP, Rybak MJ. Association Between Vancomycin Day 1 Exposure Profile and Outcomes Among Patients with Methicillin-Resistant *Staphylococcus aureus* Infective Endocarditis. *Antimicrob Agents Chemother*. 2015 Jun;59(6): 2978-85.

Claeys KC, Smith JR, **Casapao AM**, Mynatt RP, Avery L, Shroff A, Yamamura D, Davis SL, Rybak MJ. Impact of the combination of daptomycin and trimethoprim-sulfamethoxazole on clinical outcomes in methicillin-resistant *Staphylococcus aureus* infections. *Antimicrob Agents Chemother*. 2015 Apr;59(4):1969-76.

Sakoulas G, Moise PA, **Casapao AM**, Nonejuie P, Olson J, Okumura CY, Rybak MJ, Kullar R, Dhand A, Rose WE, Goff DA, Bressler AM, Lee Y, Pogliano J, Johns S, Kaatz GW, Ebright JR, Nizet V. Antimicrobial Salvage Therapy for Persistent Staphylococcal Bacteremia using Daptomycin Plus Ceftaroline. *Clin Ther*. 2014 Oct 1;36(10):1317-33.

Casapao AM, Davis SL, McRoberts JP, Lagnf AM, Patel S, Kullar R, Levine DP, Rybak MJ. Evaluation of Vancomycin Population Analysis Profile Susceptibility as a Predictor of Patient Outcomes with Methicillin-Resistant *Staphylococcus aureus* Infective Endocarditis. *Antimicrob Agents Chemother.* 2014 Aug;58(8):4636-41.

Casapao AM, Davis SL, Barr VO, Klinker KP, Goff DA, Barber KE, Kaye KS, Mynatt RP, Molloy LM, Pogue JM, Rybak MJ. A Large Multicenter Evaluation of the Effectiveness and Safety of Ceftaroline Fosamil Therapy for Severe Infections. *Antimicrob Agents Chemother.* 2014 May;58(5):2541-6.

Kullar R, **Casapao AM**, Davis SL, Levine DP, Zhao JJ, Crank CW, Segreti J, Sakoulas G, Cosgrove SE, Rybak MJ. A Multicentre Evaluation of the Effectiveness and Safety of High-Dose Daptomycin for the Treatment of Infective Endocarditis. *J Antimicrob Chemother.* 2013 Dec;68(12):2921-6.

Casapao AM, Kullar R, Davis SL, Levine DP, Zhao JJ, Potoski BA, Goff DA, Crank CW, Segreti J, Sakoulas G, Cosgrove SE, Rybak MJ. Multicenter Study of High-Dose Daptomycin for Treatment of Enterococcal Infections. *Antimicrob Agents Chemother.* 2013 Sep;57(9):4190-6.

Casapao AM, Leonard SN, Davis SL, Lodise TP, Patel N, Goff DA, LaPlante KL, Potoski BA, Rybak MJ. Clinical outcomes in patients with heterogeneous vancomycin-intermediate *Staphylococcus aureus* (hVISA) bloodstream infection. *Antimicrob Agents Chemother.* 2013 Sep;57(9):4252-9.

Casapao AM, Steed ME, Levine DP, Rybak MJ. Ceftaroline fosamil for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infection. *Expert Opin Pharmacother.* 2012 Jun;13(8):1177-86.

Abstracts

Jacobs DM, Dilworth TJ, Beyda ND, **Casapao AM**, Mashtare T, Bowers DR. Characterization of Candiduria Treatment: A Multi-Institutional Study. 117th American Society for Microbiology Microbe Conference, New Orleans, Louisiana, June 2017; Abstract # 4041.

Casapao AM, Mahlen SD. Evaluation of Ceftaroline and Telavancin Susceptibilities against Enterococcal Bloodstream Isolates. 27th European Congress of Clinical Microbiology and Infectious Diseases, Vienna, Austria, April 2017; Abstract #4328.

Casapao AM, Wungwattana M. The landscape of *Pseudomonas aeruginosa* clinical isolates in rural Northeastern United States and the Potential Impact on Hospital Mortality. 27th European Congress of Clinical Microbiology and Infectious Diseases, Vienna, Austria, April 2017; Abstract #7097.

Casapao AM, Mahlen SD. Ceftazidime-avibactam and ceftolozane-tazobactam activity against *Escherichia coli* producing CTX-M beta-lactamases. 27th European Congress of Clinical Microbiology and Infectious Diseases, Vienna, Austria, April 2017; Abstract #5215.

Kelley K, Nikornpan K, **Casapao AM**. Evaluation of Nephrotoxicity during Treatment with Vancomycin in Combination with Piperacillin-Tazobactam, Cefepime, or Meropenem. 8th Annual Husson Research and Scholarship Day, Bangor, Maine, April 20, 2017; Abstract # O-4.

Ravin K, **Casapao AM**. Effect of hospital stay duration in patients treated with aztreonam vs cefepime for gram negative empiric therapy: interim analysis. 51st Annual American Society of Hospital-System Pharmacists Midyear Clinical Meeting, Las Vegas, Nevada, December 2016; Abstract #2-160 and 8th Annual Husson Research and Scholarship Day, Bangor, Maine, April 20, 2017; Abstract # PP-2.

Laliberte NF, Ki MJ, **Casapao AM**, Wungwattana M. Susceptibility of *Pseudomonas aeruginosa* bloodstream isolates in Maine and the implications for selection of empiric antibiotic regimens. 51st Annual American Society of Hospital-System Pharmacists Midyear Clinical Meeting, Las Vegas, Nevada, December 2016; Abstract #2-179.

Rusby MLM, **Casapao AM**. Implementation of a pediatric antimicrobial stewardship in a primary care setting. 51st Annual American Society of Hospital-System Pharmacists Midyear Clinical Meeting, Las Vegas, Nevada, December 2016; Abstract #12-010.

Roy B, Owsiak R. **Casapao AM**. Statewide prevalence of Carbapenem-resistant Enterobacteriaceae from the first full year of required reporting through the Notifiable Conditions Rule. Maine Center for Disease Control and Prevention 2016 Division of Infectious Disease Annual Conference, Augusta, Maine, November 16, 2016; Abstract #11.

Casapao AM, Grieser H, Meak S, Matluck N. Clinical Impact of Further Laboratory Diagnosis for Carbapenem Resistant Enterobacteriaceae. Maine Center for Disease Control and Prevention 2016 Division of Infectious Disease Annual Conference, Augusta, Maine, November 16, 2016; Abstract #5.

Zasowski EJ, Trinh TD, Claeys KC, **Casapao AM**, Rybak MJ. Predictors of Heterogenous Vancomycin-Intermediate *Staphylococcus aureus* among Patients with Methicillin-Resistant *Staphylococcus aureus* Infective Endocarditis. 116th American Society for Microbiology Microbe Conference in conjunction with 56th Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, Massachusetts, June 2016; Abstract # 436-4.

Ki MJ, Wilson C, Wungwattana M, Malen SD, **Casapao AM**. Evaluation of Cefolozane/Tazobactam Susceptibilities of *Pseudomonas aeruginosa* Blood Isolates at Two Major Tertiary Referral Medical Centers. 116th American Society for Microbiology Microbe Conference in conjunction with 56th Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, Massachusetts, June 16-20, 2016; Abstract # 259.

Wungwattana M, Malen SD, **Casapao AM**. Susceptibility of *Pseudomonas aeruginosa* Bloodstream Isolates to Ceftazidime-Avibactam in Northeastern United States. 116th American Society for Microbiology Microbe Conference in conjunction with 56th Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, Massachusetts, June 2016; Abstract # 257.

Saab M, **Casapao AM**. Antibiotic Use in Acute Bacterial Skin and Skin Structure Infections. 7th Annual Husson Research and Scholarship Day, Bangor, Maine, April 21, 2016; Abstract # O-7.

Zasowski EJ, Trinh TD, Claeys KC, **Casapao AM**, Sabagha N, Hallesy J, Rybak MJ. Relationship between Duration of Methicillin-Resistant *Staphylococcus aureus* Bloodstream Infection and Mortality. 26th European Congress of Clinical Microbiology and Infectious Diseases, Amsterdam, Netherlands, April 2016; Abstract #6407.

Zasowski EJ, Trinh TD, Claeys KC, **Casapao AM**, Sabagha N, Rybak MJ. Ceftaroline Fosamil for the Treatment of Methicillin-Resistant *Staphylococcus aureus* Infective Endocarditis. 26th European Congress of Clinical Microbiology and Infectious Diseases, Amsterdam, Netherlands, April 2016; Abstract #6408.

Leichtweis CL, **Casapao AM**, Boudreau M, Mahlen S. Evaluation of empiric antimicrobial therapy and resistance of catheter-associated urinary tract infections versus non-catheter associated urinary tract infections in a level II trauma center. 50th Annual American Society of Hospital-System Pharmacists Midyear Clinical Meeting, New Orleans, Louisiana, December 2015; Abstract #12-055. *Encore presentation*: 35th Annual Eastern States Conference, Hersey, Pennsylvania, May 2015.

Lee J. **Casapao AM**, Marston M. Evaluation of empiric and definitive therapy for febrile neutropenia. 50th Annual American Society of Hospital-System Pharmacists Midyear Clinical Meeting, New Orleans, Louisiana, December 2015; Abstract #2-119.

Wilson C. Graffam J. **Casapao AM**, Mahlen S. Evaluation of ceftolozane/tazobactam susceptibilities in *Pseudomonas aeruginosa* bloodstream isolates at level II trauma tertiary hospital. 50th Annual American Society of Hospital-System Pharmacists Midyear Clinical Meeting, New Orleans, Louisiana, December 2015; Abstract #2-129.

Rusby M. Thorton L, Ng YT, **Casapao AM**. Pharmacoepidemiology of pediatric patients with bronchiolitis. 50th Annual American Society of Hospital-System Pharmacists Midyear Clinical Meeting, New Orleans, Louisiana, December 2015; Abstract #2-125. *Encore presentations*: Pediatric Pharmacy Advocacy Group 25th Annual Conference, Atlanta, Georgia, May 2016; Abstract # 88 and 7th Annual Husson Research and Scholarship Day, Bangor, Maine, April 21, 2016; Abstract # O-6.

Tran K, **Casapao AM**. Pharmacoepidemiology of Enterobacter infections at a level two tertiary medical center. 50th Annual American Society of Hospital-System Pharmacists Midyear Clinical Meeting, New Orleans, Louisiana, December 2015; Abstract #2-126.

Casapao AM, Jacobs DM, Bowers DR, Beyda NE, Dilworth TJ. Early Beta-Lactam Therapy Combined with Standard Therapy for Methicillin-Resistant *Staphylococcus aureus* Bloodstream Infections compared to Standard Alone: A Multicenter, Retrospective, Propensity-Matched Analysis. 55th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, California, September 17-21, 2015; Abstract #B-071.

Rusby M, Wilson C, **Casapao AM**. Impact of Mortality and Source of Infection in Intermediate Risk Patients with *Staphylococcus aureus* Bacteremia. 55th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, California, September 17-21, 2015; Abstract #K815.

Wilson C, Rusby M, **Casapao AM**. Epidemiological Study of Obese Patients with *Staphylococcus aureus* Bacteremia at Eastern Maine Medical Center. 55th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, California, September 17-21, 2015; Abstract #K814.

Zasowski EJ, Claeys KC, **Casapao AM**, Sabagha N, Klinker KP, Davis SL, Rybak MJ. Ceftaroline fosamil for the Treatment of Methicillin-Resistant *Staphylococcus aureus* Pneumonia.

55th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, California, September 17-21, 2015; Abstract #B-081.

Zasowski EJ, Claeys KC, **Casapao AM**, Sabagha N, Klinker KP, Davis SL, Rybak MJ. Ceftaroline fosamil for the treatment of Methicillin-Resistant *Staphylococcus aureus* Bloodstream Infections. 55th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, California, September 17-21, 2015; Abstract #B-079.

Trafton M, **Casapao AM**, Seavey W, Boudreau M. Quasi-Experimental Study to Evaluate Drug Administration Complications with the Use of Extended Infusion Piperacillin/Tazobactam. 34th Annual Eastern States Conference, Hersey, Pennsylvania, May 2015.

Zasowski EJ, Lagnf AM, **Casapao AM**, Rybak MJ. Impact of Delayed Antibiotic Therapy on Outcomes of Patients with Hospital-Onset Enterococcal Bacteremia (EB): A Retrospective Cohort Study. 25th European Congress of Clinical Microbiology and Infectious Diseases, Copenhagen, Denmark, April 2015; Abstract #eP163.

Pelletier J, **Casapao AM**. Analysis of Antimicrobial Therapy Optimization in Patients with *Escherichia coli* Bacteremia. 6th Annual Husson Research and Scholarship Day, Bangor, Maine, April 23, 2015; Abstract #PP-6.

Nya P, **Casapao AM**. Evaluation of *Staphylococcus aureus* Bacteremia in Adults with Renal Disease. 6th Annual Husson Research and Scholarship Day, Bangor, Maine, April 23, 2015; Abstract #PP-5.

Mehta, RM, **Casapao, AM**. The Impact of Erythromycin Resistance of Patients with *Staphylococcus aureus* Bacteremia. 6th Annual Husson Research and Scholarship Day, Bangor, Maine, April 23, 2015; Abstract #PP-4.

Egharevba E, **Casapao, AM**. Infectious Diseases Consultation May Improve Treatment Outcome Associated with *Staphylococcus aureus* Bacteremia. 6th Annual Husson Research and Scholarship Day, Bangor, Maine, April 23, 2015; Abstract #PP-2.

Akwuba V, **Casapao AM**. Clinical Outcomes of *Staphylococcus aureus* Bacteremia in Intravenous Drug Users. 6th Annual Husson Research and Scholarship Day, Bangor, Maine, April 23, 2015; Abstract #PP-1.

Duron A, **Casapao AM**. Eastern Maine Medical Center Quality Improvement Review of Optimizing Ceftriaxone Therapy. 6th Annual Husson Research and Scholarship Day, Bangor, Maine, April 23, 2015; Abstract #O-6.

Rusby M, **Casapao AM**. Mortality Rates in Low-Risk, Intermediate-Risk, and High-Risk Patients. 6th Annual Husson Research and Scholarship Day, Bangor, Maine, April 23, 2015; Abstract #O-8.

Wilson C, **Casapao AM**. An Epidemiological Study of Obese Patients with *Staphylococcus aureus* Bacteremia at Eastern Maine Medical Center. 6th Annual Husson Research and Scholarship Day, Bangor, Maine, April 23, 2015; Abstract #O-9.

Casapao AM, Lagnf AM, Rybak MJ. Temporal Characterization of Patients with Enterococcal Bloodstream Infection. 2014 Division of Infectious Disease Annual Conference, Augusta, Maine, November 19, 2014.

Trafton M, Boudreau M, Seavey W, **Casapao AM**. A Quasi-Experimental Study to Evaluate Drug Administration Complication in the Use of Extended Infusion Piperacillin/Tazobactam. 49th Annual American Society of Hospital-System Pharmacists Midyear Clinical Meeting, Anaheim, California, December 2014; Abstract #10-187.

Casapao AM, Lagnf AM, Rybak MJ. Temporal Characterization of Patients with Enterococcal Bloodstream Infection. 54th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington D.C., September 5-9, 2014; Abstract #K1665.

Claeys KC, **Casapao AM**, Davis SL, Rybak MJ. Burden of Illness with Acute Bacterial Skin and Skin Structure Infections Evaluated in the Emergency Department or Observational Unit: Experience at the Detroit Medical Center. 54th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington D.C., September 5-9, 2014; Abstract #K1702.

Nagel JL, Pogue J, Claeys KC, **Casapao AM**, Finks J, Rybak MJ. Utilization of the Centers for Disease Control and Prevention National Healthcare Safety Network Antimicrobial Use and Resistance Module to Compare Multicenter Antimicrobial Use. 54th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington D.C., September 5-9, 2014; Abstract #K332.

Claeys KC, Nagel JL, **Casapao AM**, Pogue JM, Finks J, Davis SL, Rybak MJ. Implementing the National Healthcare Safety Network's Antimicrobial Use Option to Aid in Determination of Resistance Among Key Nosocomial Pathogens. 54th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington D.C., September 5-9, 2014; Abstract #K327.

Nagel JL, Pogue JM, Claeys KC, **Casapao AM**, Finks J, Davis SL, Rybak MJ. Utilization of the Center for Disease Control Antimicrobial Use and Resistance Module to Compare Multicenter Antimicrobial Prescribing on Medical, Surgical, and Intensive Care Units. 17th Annual Making a Difference in Infectious Diseases Pharmacotherapy Meeting, Orlando, FL, May 2014.

Claeys KC, Nagel JL, Pogue JM, **Casapao AM**, Finks J, Davis SL, Rybak MJ. Implementing the National Healthcare Safety Network's Antibiotic Utilization and Resistance Program to Determine Resistance Among Key Nosocomial Pathogens. 17th Annual Making a Difference in Infectious Diseases Pharmacotherapy Meeting, Orlando, FL, May 2014.

Casapao AM, Davis SL, Barr VO, Goff DA, Kaye KS, Pogue JM, Rybak MJ. Retrospective Multi-Centre Experience of the Effectiveness and Safety with Ceftaroline Fosamil Therapy in Patients with Acute Bacterial Skin and Skin Structure Infections. 24th European Congress of Clinical Microbiology and Infectious Diseases, Barcelona, Spain, May 2014; Abstract #eP422.

Casapao AM, Davis SL, Barr VO, Klinker KP, Goff DA, Barber KE, Steinke LM, Mynatt RP, Kaye KS, Pogue JM, Rybak MJ. The Effectiveness and Safety with Ceftaroline Fosamil Therapy for Lower Respiratory Tract Infections in a Retrospective Multi-Centre Study. 24th European Congress of Clinical Microbiology and Infectious Diseases, Barcelona, Spain, May 2014; Abstract #eP425.

Claeys KC, **Casapao AM**, Pogue JM, Bhatia N, Mynatt RP, Saely S, Arthur C, Welch R, Sherwin R, Hafeez W, Levine DP, Kaye KS, Delgado Jr. G, Giuliano CA, Takla R Johnson LB, Davis SL, Rybak MJ. Rapid Diagnostic Testing with GeneXpert Improves Enrollment in a Randomised Clinical Trial for Detection of Methicillin-Resistant *Staphylococcus aureus* in Acute Bacterial Skin and Skin Structure Infections. 24th European Congress of Clinical Microbiology and Infectious Diseases, Barcelona, Spain, May 2014; Abstract #P1471.

Bentley K, Epps K, Cannon C, **Casapao AM**, Tucker C. Evaluation of the Efficacy of Extended Infusion Piperacillin-Tazobactam Administration in Non-Intensive Care Unit Patients. 3rd Annual Florida Residency Conference and Florida Society of Health-system Pharmacists, Gainesville, FL May 2014.

Weissman A, Yiannos L, Ge, E, Mynatt RP, Rybak MJ, Millis S, **Casapao AM**, Levy P. A Retrospective Review of Empiric Antibiotic Selection in Patients Admitted with Urinary Tract Infection. 18th Annual New England Regional Society for Academic Emergency Medicine, New Haven, CT March 2014; Abstract #32A.

Weissman A, Yiannos L, Ge, E, Mynatt RP, Rybak MJ, Millis S, **Casapao AM**, Levy P. Appropriateness of Outpatient Empiric Antibiotic Selection in Patients with Urinary Tract Infections. 18th Annual New England Regional Society for Academic Emergency Medicine, New Haven, CT March 2014; Abstract #32.

Ni D, Rising K, **Casapao AM**, Barber KE, Mynatt RP, Rybak MJ. Vancomycin Consensus Guidelines Application and Serum Concentration Target Attainment. 48th ASHP Midyear Clinical Meeting Orlando, FL, December 2013; Abstract #1-316.

Casapao AM, Davis SL, Barr VO, Klinker KP, Goff DA, Barber KE, Steinke LM, Mynatt RP, Kaye KS, Pogue JM, Rybak MJ. Multicenter Experience of the Effectiveness and Safety with Ceftaroline Fosamil (CPT) Therapy. 10th Annual Research Forum; Eugene Applebaum College of Pharmacy and Health Sciences, Detroit, MI, October 2013; Abstract #20.

Claeys KC, **Casapao AM**, Goff DA, Kaye KS, Levine DP, Davis SL, Rybak MJ. Daptomycin versus Vancomycin for Bloodstream Infection caused by Methicillin-Resistant *Staphylococcus aureus* (MRSA) Preliminary Results. 10th Annual Research Forum; Eugene Applebaum College of Pharmacy and Health Sciences, Detroit, MI, October 2013; Abstract #68.

Claeys KC, **Casapao AM**, Pogue JM, Bhatia N, Mynatt RP, Saely S, Arthur C, Welch R, Sherwin R, Hafeez W, Levine DP, Kaye KS, Delgado G, Giuliano CA, Takla R, Johnson LB, Davis SL, Rybak MJ. Characterization of Patients Treated for Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Documented or at Risk of Methicillin-Resistant *Staphylococcus aureus* (MRSA). 10th Annual Research Forum; Eugene Applebaum College of Pharmacy and Health Sciences, Detroit, MI, October 2013; Abstract #67.

Ni D, Rising K, **Casapao AM**, Barber KE, Mynatt RP, Rybak MJ. Vancomycin Consensus Guidelines Application and Serum Concentration Target Attainment. 10th Annual Research Forum; Eugene Applebaum College of Pharmacy and Health Sciences, Detroit, MI, October 2013; Abstract #35.

Divekar P, **Casapao AM**, Firestone SM, Rybak MJ, Martin ET. Comparative Study of Prevalence of pSK41 in Heterogeneous Vancomycin-Intermediate *Staphylococcus aureus* (hVISA) Isolates Against non-hVISA Isolates. 10th Annual Research Forum; Eugene Applebaum College of Pharmacy and Health Sciences, Detroit, MI, October 2013; Abstract #75.

Casapao AM, Davis SL, Barr VO, Klinker KP, Goff DA, Barber KE, Steinke LM, Mynatt RP, Kaye KS, Pogue JM, Rybak MJ. Multicenter Experience of the Effectiveness and Safety with Ceftaroline Fosamil (CPT) Therapy. 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Denver, CO, September 10-13, 2013; Abstract # K-192.

McRoberts JP, **Casapao AM**, Lephart PR, Rybak MJ. Evaluation of Methicillin-Resistant *Staphylococcus aureus* (MRSA) Bloodstream Infections (BSI) Minimum Inhibitory Concentrations (MICs) to Vancomycin (VA) and Daptomycin (DAP) at an Urban Detroit Medical Institution. 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Denver, CO, September 10-13, 2013; Abstract # C2-080.

Casapao AM, Davis SL, Levine DP, Rybak MJ. Characterization of Patients with Methicillin-Resistant *Staphylococcus aureus* (MRSA) Infective Endocarditis (IE). 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Denver, CO, September 10-13, 2013; Abstract # K-1285.

Casapao AM, Davis SL, Kullar R, Patel S, Levine DP, Rybak MJ. An Alternative Susceptibility Method as Predictor of Clinical Response to Vancomycin (VAN) with Methicillin-Resistant *Staphylococcus aureus* (MRSA) Infective Endocarditis (IE). 21st Annual Infectious Diseases Pharmacotherapy Fellowship Forum, York Harbor, ME, May 2013; Abstract #10.

Casapao AM, Davis SL, Kullar R, Patel S, Levine DP, Rybak MJ. An Alternative Susceptibility Method as Predictor of Clinical Response to Vancomycin (VAN) with Methicillin-Resistant *Staphylococcus aureus* (MRSA) Infective Endocarditis (IE). 12th International Symposium on Modern Concepts in Endocarditis and Cardiovascular Infections, International Society of Cardiovascular Infectious Diseases (ISCVID), Dubrovnik, Croatia, May 2013; Abstract # P41.

Casapao AM, Barber KE, Wong CK, Barr V, Steinke LM, Mynatt RP, Davis SL, Kaye KS, Pogue JM, Rybak MJ. Clinical experience with ceftaroline fosamil (CPT) for bloodstream infections (BSI). 23rd European Congress of Clinical Microbiology and Infectious Diseases, Berlin, Germany, April 2013; Abstract # 3369.

Casapao AM, Patel S, Kullar R, Davis SL, Levine DP, Rybak MJ. Evaluation of vancomycin exposure on outcomes in a cohort of patients with methicillin-resistant *Staphylococcus aureus* (MRSA) infective endocarditis (IE). 23rd European Congress of Clinical Microbiology and Infectious Diseases, Berlin, Germany, April 2013; Abstract # 2655.

Casapao AM, Barber KE, Wong CK, Steinke LM, Mynatt RP, Davis SL, Kaye KS, Pogue JM, Rybak MJ. Early Experience with Ceftaroline fosamil Therapy at an Academic Hospital System. 9th Annual Research Forum; Eugene Applebaum College of Pharmacy and Health Sciences, Detroit, MI, October 2012; Abstract #10.

Barber KE, Pogue JM, **Casapao AM**, Rybak MJ. Outcomes Associated with Vancomycin Intermediate *Staphylococcus aureus* (VISA) Bloodstream Infections (BSI). 9th Annual Research Forum; Eugene Applebaum College of Pharmacy and Health Sciences, Detroit, MI, October 2012; Abstract #43.

Casapao AM, Patel S, Kullar R, Davis SL, Rybak MJ. Evaluation of Population Analysis Profile Susceptibility (PAP) as a Predictor of Patient Outcomes with Methicillin-Resistant *Staphylococcus aureus* (MRSA) Infective Endocarditis (IE). 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 9-12, 2012; Abstract #K-946.

Casapao AM, Kullar R, Davis SL, Levine DP, Zhao JJ, Potoski BA, Goff DA, Crank CW, Segreti J, Sakoulas G, Cosgrove SE, Rybak MJ. High-Dose Daptomycin for Treatment of Enterococcal Infections: Multicenter, Retrospective Study. 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 9-12, 2012; Abstract #K-275.

Barber KE, **Casapao AM**, Pogue JM, Kaye KS, Rybak MJ. Outcomes Associated with Vancomycin Intermediate *Staphylococcus aureus* (VISA) Bloodstream Infections (BSI). 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 9-12, 2012; Abstract #K-906.

Casapao AM, Leonard SN, Davis SL, Lodise TP, Patel N, Goff DA, Laplante KL, Potoski BA, Rybak MJ. Clinical Outcomes in Patients with Heterogeneous Vancomycin-Intermediate *Staphylococcus aureus* (hVISA). 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 9-12, 2012; Abstract #K-1123.

Casapao AM, Barber KE, Wong CK, Steinke LM, Mynatt RP, Davis SL, Kaye KS, Pogue JM, Rybak MJ. Early Experience with Ceftaroline fosamil Therapy at an Academic Hospital System. 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 9-12, 2012; Abstract #K-909.

Martin ET, **Casapao AM**, McRoberts J, Archer C, Kaye KS, Rybak MJ. Low prevalence of Inc18-like *vanA* plasmid among prospectively-collected vancomycin-resistant *Enterococcus* isolates from Detroit Medical Center. 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 9-12, 2012; Abstract #C2-1985.

Casapao AM, Leonard SN, Davis SL, Lodise TP, Patel N, Goff DA, Laplante KL, Potoski BA, Rybak MJ. Clinical Outcomes in Patients with Heterogeneous Vancomycin-Intermediate *Staphylococcus aureus* (hVISA). Star of the North 20th Annual Infectious Diseases Pharmacotherapy Fellowship Forum, Brainerd, MN, June 2012.

Casapao AM, Barber KE, Wong CK, Steinke LM, Mynatt RP, Davis SL, Kaye KS, Pogue JM, Rybak MJ. Ceftaroline fosamil Therapy for *Staphylococcus aureus* Infections. 15th Making A Difference in Infectious Diseases Pharmacotherapy, Orlando, FL, March 2012; Abstract #5-OR FRS.

Kasha MZ, Barber KE, **Casapao AM**, Mynatt RP, Rybak MJ. Vancomycin Consensus Guidelines Application and Serum Concentration Target Attainment: A Quality Assessment Evaluation. 46th Annual American Society of Health System Pharmacists Midyear Clinical Meeting, New Orleans, LA, December 2011; Abstract #4-157.

Casapao AM, Kullar R, Leonard SN, Davis SL, Kaatz GW, Patel N, Lodise TP, Goff DA, Potoski BA, LaPlante KL, Rybak MJ. Clinical Outcomes in Patients with Vancomycin Heteroresistant *Staphylococcus aureus*. 8th Annual Research Forum; Eugene Applebaum College of Pharmacy and Health Sciences, Detroit, MI, October 2011; Abstract #61.

Casapao AM, Potoski BA, Doi Y, Pasculle AW. *In vitro* susceptibilities of Fosfomycin against Enterobacteriaceae producing KPC-type Beta-lactamases. 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Chicago, IL, September 17-20, 2011; Abstract #E-725.

Armahizer MJ, **Casapao AM**, Potoski BA. Persistent Bacteremia in a patient due to Vancomycin-Intermediate *Staphylococcus aureus* (VISA). 45th Annual American Society of Health System Pharmacists Midyear Clinical Meeting, Anaheim, CA, December 2010; Abstract #6-150.

Casapao AM, Stafford L, Loudy M, Epps K. Extended Infusion Beta-Lactam Antibiotic Administration in Critically Ill Adult Patients. 41st Southeastern Residency Conference, Athens, GA, April 29-30 2009.

Casapao AM, Stafford L, Loudy M, Epps K. Extended Infusion Beta-Lactam Antibiotic Administration in Critically Ill Adult Patients. 44th Annual American Society of Health System Pharmacists Midyear Clinical Meeting, Las Vegas, NV, December 2009; Abstract #7-125.

Research Platform Presentations

Casapao AM, Davis SL, Kullar R, Levine DP, Rybak MJ. An Alternative Susceptibility Method as Predictor of Clinical Response to Vancomycin (VAN) with Methicillin-Resistant *Staphylococcus aureus* (MRSA) Infective Endocarditis. 21st Annual Infectious Diseases Pharmacotherapy Fellowship Forum, York Harbor, ME, May 2013; Abstract #10.

Casapao AM, Patel S, Kullar R, Davis SL, Levine DP, Rybak MJ. Evaluation of vancomycin exposure on outcomes in a cohort of patients with methicillin-resistant *Staphylococcus aureus* (MRSA) infective endocarditis (IE). 23rd European Congress of Clinical Microbiology and Infectious Diseases, Berlin, Germany, April 29, 2013; Abstract #2655.

Casapao AM, Leonard SN, Davis SL, Lodise TP, Patel N, Goff DA, Laplante KL, Potoski BA, Rybak MJ. Clinical Outcomes in Patients with Heterogeneous Vancomycin-Intermediate *Staphylococcus aureus* (hVISA). 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 9-12, 2012; Abstract #K-1123.

Casapao AM, Leonard SN, Davis SL, Lodise TP, Patel N, Goff DA, Laplante KL, Potoski BA, Rybak MJ. Clinical Outcomes in Patients with Heterogeneous Vancomycin-Intermediate *Staphylococcus aureus* (hVISA). Star of the North 20th Annual Infectious Diseases Pharmacotherapy Fellowship Forum, Brainerd, MN, June 2012; Abstract #21.

Casapao AM, Stafford L, Loudy M, Epps K. Extended Infusion Beta-Lactam Antibiotic Administration in Critically Ill Adult Patients. 41st Southeastern Residency Conference, Athens, GA, April 29-30 2009.

Research Posters

Casapao AM, Mahlen SD. Evaluation of Ceftaroline and Telavancin Susceptibilities against Enterococcal Bloodstream Isolates. 27th European Congress of Clinical Microbiology and Infectious Diseases, Vienna, Austria, April 2017; Abstract #4328.

Casapao AM, Wungwattana M. The landscape of *Pseudomonas aeruginosa* clinical isolates in rural Northeastern United States and the Potential Impact on Hospital Mortality. 27th European Congress of Clinical Microbiology and Infectious Diseases, Vienna, Austria, April 2017; Abstract #7097.

Casapao AM, Mahlen SD. Ceftazidime-avibactam and ceftolozane-tazobactam activity against *Escherichia coli* producing CTX-M beta-lactamases. 27th European Congress of Clinical Microbiology and Infectious Diseases, Vienna, Austria, April 2017; Abstract #5215.

Casapao AM, Grieser H, Meak S, Matluck N. Clinical Impact of Further Laboratory Diagnosis for Carbapenem Resistant Enterobacteriaceae. Maine Center for Disease Control and Prevention 2016 Division of Infectious Disease Annual Conference, Augusta, Maine, November 16, 2016; Abstract #5.

Casapao AM, Jacobs DM, Bowers DR, Beyda NE, Dilworth TJ. Early Beta-Lactam Therapy Combined with Standard Therapy for Methicillin-Resistant *Staphylococcus aureus* Bloodstream Infections compared to Standard Alone: A Multicenter, Retrospective, Propensity-Matched Analysis. 55th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, California, September 17-21, 2014; Abstract #B-071.

Casapao AM, Lagnf AM, Rybak MJ. Temporal Characterization of Patients with Enterococcal Bloodstream Infection. 54th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington D.C., September 5-9, 2014; Abstract #K-1665.

Casapao AM, Davis SL, Barr VO, Goff DA, Kaye KS, Pogue JM, Rybak MJ. Retrospective Multi-Centre Experience of the Effectiveness and Safety with Ceftaroline Fosamil Therapy in Patients with Acute Bacterial Skin and Skin Structure Infections. 24th European Congress of Clinical Microbiology and Infectious Diseases, Barcelona, Spain, May 2014; Abstract #eP422.

Casapao AM, Davis SL, Barr VO, Klinker KP, Goff DA, Barber KE, Steinke LM, Mynatt RP, Kaye KS, Pogue JM, Rybak MJ. The Effectiveness and Safety with Ceftaroline Fosamil Therapy for Lower Respiratory Tract Infections in a Retrospective Multi-Centre Study. 24th European Congress of Clinical Microbiology and Infectious Diseases, Barcelona, Spain, May 2014; Abstract #eP425.

Casapao AM, Davis SL, Barr VO, Klinker KP, Goff DA, Barber KE, Steinke LM, Mynatt RP, Kaye KS, Pogue JM, Rybak MJ. Multicenter Experience of the Effectiveness and Safety with Ceftaroline Fosamil (CPT) Therapy. 10th Annual Research Forum; Eugene Applebaum College of Pharmacy and Health Sciences, Detroit, MI, October 2013; Abstract #20.

Casapao AM, Barber KE, Wong CK, Barr V, Steinke LM, Mynatt RP, Davis SL, Kaye KS, Pogue JM, Rybak MJ. Clinical experience with ceftaroline fosamil (CPT) for bloodstream infections (BSI). 23rd European Congress of Clinical Microbiology and Infectious Diseases, Berlin, Germany, April 27-30, 2013; Abstract # 3369.

Casapao AM, Barber KE, Wong CK, Steinke LM, Mynatt RP, Davis SL, Kaye KS, Pogue JM, Rybak MJ. Early Experience with Ceftaroline fosamil Therapy at an Academic Hospital System. 9th Annual Research Forum; Eugene Applebaum College of Pharmacy and Health Sciences, Detroit, MI, October 2012; Abstract #10.

Casapao AM, Patel S, Kullar R, Davis SL, Rybak MJ. Evaluation of Population Analysis Profile Susceptibility (PAP) as a Predictor of Patient Outcomes with Methicillin-Resistant *Staphylococcus aureus* (MRSA) Infective Endocarditis (IE). 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 2012; Abstract #K-946.

Casapao AM, Kullar R, Davis SL, Levine DP, Zhao JJ, Potoski BA, Goff DA, Crank CW, Segreti J, Sakoulas G, Cosgrove SE, Rybak MJ. High-Dose Daptomycin for Treatment of Enterococcal Infections: Multicenter, Retrospective Study. 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 2012; Abstract #K-275.

Casapao AM, Barber KE, Wong CK, Steinke LM, Mynatt RP, Davis SL, Kaye KS, Pogue JM, Rybak MJ. Early Experience with Ceftaroline fosamil Therapy at an Academic Hospital System. 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 9-12, 2012; Abstract #K-909.

Casapao AM, Barber KE, Wong CK, Steinke LM, Mynatt RP, Davis SL, Kaye KS, Pogue JM, Rybak MJ. Ceftaroline fosamil Therapy for *Staphylococcus aureus* Infections. 15th Making A Difference in Infectious Diseases Pharmacotherapy, Orlando, FL, March 2012; Abstract #5-OR FRS.

Casapao AM, Kullar R, Leonard SN, Davis SL, Kaatz GW, Patel N, Lodise TP, Goff DA, Potoski BA, LaPlante KL, Rybak MJ. Clinical Outcomes in Patients with Vancomycin Heteroresistant *Staphylococcus aureus*. 8th Annual Research Forum; Eugene Applebaum College of Pharmacy and Health Sciences, Detroit, MI, October 2011; Abstract #61.

Casapao AM, Potoski BA, Doi Y, Pasculle AW. *In vitro* susceptibilities of Fosfomycin against Enterobacteriaceae producing KPC-type Beta-lactamases. 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Chicago, IL, September 17-20, 2011; Abstract #E-725.

Armahizer MJ, **Casapao AM**, Potoski BA. Persistent Bacteremia in a patient due to Vancomycin-Intermediate *Staphylococcus aureus* (VISA). 45th Annual American Society of Health System Pharmacists Midyear Clinical Meeting, Anaheim, CA, December 2010; Abstract #6-150.

Casapao AM, Stafford L, Loudy M, Epps K. Extended Infusion Beta-Lactam Antibiotic Administration in Critically Ill Adult Patients. 44th Annual American Society of Health System Pharmacists Midyear Clinical Meeting, Las Vegas, NV, December 2009; Abstract #7-125.

Journal Peer Reviewer

Infectious Diseases and Therapy

Clinical Therapeutics

PLOS ONE

Pharmacotherapy

Annals of Pharmacotherapy (DICP)

Antimicrobial Agents Chemotherapy

Journal Peer Reviewer cont.

Clinical Infectious Diseases
American Journal of the Medical Sciences
Infection Control and Hospital Epidemiology
F1000 Medicine Reports

Teaching Experience

Advanced Pharmacy Practice Experience (RX611) Infectious Diseases Clinical Clerkship Rotation. Husson University School of Pharmacy/Eastern Maine Medical Center. P4 PharmD Candidates. Preceptor (5 days for 6 weeks) and Course Coordinator: Fall 2014, Spring 2015, Summer 2015, Fall 2015, Winter 2016, Spring 2016, Summer 2016, Fall 2016, Winter 2017, and Spring 2017.

Infectious Diseases Research (RX 490). Husson University School of Pharmacy. P1, P2, and P3 PharmD Candidates. Course Coordinator/Lecturer. Spring 2015, Summer 2015, Fall 2015, Summer 2016, Fall 2016, Spring 2017 and Summer 2017.

Pharmacy Capstone (RX542). Husson University School of Pharmacy. P3 PharmD Candidates. Course Coordinator/Lecturer. Spring 2015, 2016, and 2017.

Pharmacotherapeutics I (RX474). Husson University School of Pharmacy. P2 PharmD Candidates. Lecturer. Introduction and Review of Antimicrobial Agents, Pharmacokinetics of Vancomycin and Aminoglycosides. Spring 2016 and 2017.

Medical Microbiology (RX342). Husson University School of Pharmacy. P1 PharmD Candidates. Lecturer. Spring 2015, 2016, and 2017.

Pharmacotherapeutics III (RX522). Husson University School of Pharmacy. P3 PharmD Candidates. Lecturer. Sexual Transmitted Infections, Urinary Tract Infections and Meningitis. Spring 2017.

Applied Pharmacotherapeutics II Recitation (RX592). Husson University School of Pharmacy. P3 PharmD Candidates. Lecturer/Facilitator. Sexual Transmitted Infections and Meningitis. Spring 2015, 2016 and 2017.

Introductory Pharmacy Practice Experiential (RX550) Infectious Diseases Research. Husson University School of Pharmacy/Eastern Maine Medical Center. P3 PharmD Candidates. Preceptor (5 days for 3 weeks) Winter 2015, 2016, and 2017.

Infectious Diseases Pharmacotherapy Elective (RX 569). Husson University School of Pharmacy. P3 PharmD Candidates. Course Coordinator/Lecturer/Facilitator. Fall 2016.

Principals of Pharmacokinetics (RX433). Husson University School of Pharmacy. P2 PharmD Candidates. Lecturer. Fall 2015 and 2016.

Applied Pharmacotherapeutics I Recitation (RX591). Husson University School of Pharmacy. P3 PharmD Candidates. Lecturer. Pneumonia and Infective Endocarditis. Fall 2016.

Pharmacotherapeutics II (RX521). Husson University School of Pharmacy. P3 PharmD Candidates. Lower respiratory tract Infections and Infective Endocarditis. Fall 2016.

NAPLEX Live Review Session. Husson University School of Pharmacy. Recent P4 PharmD graduates. Lecturer. Infectious Diseases Pharmacotherapy Review. Summer 2015 and 2016.

PGY2 Infectious Diseases Microbiology Rotation. Eastern Maine Medical Center. PGY-2 Infectious Disease Residency. Preceptor (5 days for 2 weeks) Summer 2016.

PGY1 Infectious Diseases Clinical Rotation. Eastern Maine Medical Center. PGY-1 Pharmacy Practice Residency. Preceptor (5 days for 4 weeks) Winter 2015, Spring 2015, and Summer 2016. Co-Preceptor (2-3 days for 4 weeks) Fall 2016 and Spring 2017.

Critical Care Pharmacotherapy (RX582). Husson University School of Pharmacy. P3 PharmD Candidates. Lecturer. Antimicrobial Therapy Considerations in Critically Ill Population. Spring 2016.

Drug-Drug Interactions (RX564). Husson University School of Pharmacy. P2 and P3 PharmD Candidates. Lecturer. Gastrointestinal Drug-Drug Interactions. Spring 2015 and 2016.

Drug Action VI (RX522). Husson University School of Pharmacy. P3 PharmD Candidates. Lecturer. Sexual Transmitted Infections and Meningitis. Spring 2015 and 2016.

Cognitive, Communication, and Case-Based Critical Thinking IV (RX432). Husson University School of Pharmacy. P2 PharmD Candidates. Lecturer/Facilitator. Spring 2015 and 2016.

Advanced Pharmacy Practice Experience (RX617) Pharmacy Research in Infectious Diseases Rotation. Husson University School of Pharmacy/Eastern Maine Medical Center. P4 PharmD Candidates. Preceptor (5 days for 6 weeks) Fall 2015 and Fall 2016.

Pharmacy Seminar (RX551). Husson University School of Pharmacy. P3 PharmD Candidates. Lecturer. Drug Literature Evaluation. Fall 2014 and 2015.

Applied Pharmacotherapeutics I Recitation (RX591). Husson University School of Pharmacy. P3 PharmD Candidates. Lecturer. Introduction and Review of Antimicrobial Agents, Pharmacokinetics of Vancomycin and Aminoglycosides, Pneumonia, Infective Endocarditis, and Urinary Tract Infections. Fall 2014 and 2015.

Drug Action V (RX521). Husson University School of Pharmacy. P3 PharmD Candidates. Lecturer. Introduction and Review of Antimicrobial Agents, Pharmacokinetics of Vancomycin and Aminoglycosides, Pneumonia, Infective Endocarditis, and Urinary Tract Infections. Fall 2014 and 2015.

Geriatric Pharmacotherapy Elective (RX490.001). Husson University School of Pharmacy. P3 PharmD Candidates. Lecturer. Respiratory, Renal, and Urological Disorders in Elderly Population. Summer 2014.

PGY2 Infectious Diseases Consult Rotation. Detroit Receiving Hospital. PGY-2 Residency. Co-Preceptor (5 days for 4 weeks) Fall 2011, 2012, and 2013.

Principles of Pharmacotherapy 3 (PHA 4210) – Respiratory and Infectious Diseases Pharmacotherapy. Wayne State University Eugene Applebaum College of Pharmacy and Health Sciences. P2 PharmD Candidates. Lecturer. Skin and Soft Tissue Infections and Surgical Prophylaxis. Winter 2012 and 2013.

Pharmacotherapy Problem Solving (PHA 5270). Wayne State University Eugene Applebaum College of Pharmacy and Health Sciences. P3 PharmD Candidates. Co-Facilitator (1 day/week) Spring 2012.

Advanced Pharmacy Practice Patient Care Elective (APPE) (PPR7530): Infectious Diseases Consult Rotation. Wayne State University Eugene Applebaum College of Pharmacy and Health Sciences/Detroit Receiving Hospital. P4 PharmD Candidates. Co-Preceptor (5 days for 6 weeks) Fall 2011, Spring 2012, and Fall 2012.

Directed Study in Pharmacy Practice (PPR 7990). Wayne State University Eugene Applebaum College of Pharmacy and Health Sciences. P2 PharmD Candidates. Co-Facilitator. Summer 2012 and 2013.

PGY1 Infectious Diseases Consult Rotation. University of Pittsburgh Medical Center-Presbyterian Hospital. PGY-1 Residency. Co-Preceptor (5 days for 4 weeks) Spring 2011.

Advanced Pharmaceutical Care 2 (PHARM 5321). University of Pittsburgh School of Pharmacy. P3 PharmD Candidates. Facilitator. Spring 2011.

Pharmacotherapy of Infectious Diseases 2 (PHARM 5215). University of Pittsburgh School of Pharmacy. P2 PharmD Candidates. Lecturer. Introduction to Mycoses. Spring 2011.

Pharmacotherapy of Infectious Diseases 2 (PHARM 5215). University of Pittsburgh School of Pharmacy. P2 PharmD Candidates. Lecturer. Candidiasis. Spring 2011.

Advanced Pharmaceutical Care 1 (PHARM 5225). University of Pittsburgh School of Pharmacy. P2 PharmD Candidates. Facilitator. Spring 2011.

Profession of Pharmacy 2 (PHARM 5111). University of Pittsburgh School of Pharmacy. P1 PharmD Candidates. Facilitator. Spring 2011.

Pharmacotherapy of Gastroenterology/Nutrition (PHARM 5223). University of Pittsburgh School of Pharmacy. P2 PharmD Candidates. Facilitator. Spring 2011.

Pharmacotherapy of Cardiovascular Diseases (PHARM 5216). University of Pittsburgh School of Pharmacy. P2 PharmD Candidates. Facilitator. Fall 2010.

Profession of Pharmacy 1 (PHARM 5110). University of Pittsburgh School of Pharmacy. P1 PharmD Candidates. Facilitator. Fall 2010.

Advanced Pharmacy Practice Experience (APPE) 2 (PHARM 5402) Infectious Diseases Consult Rotation. University of Pittsburgh School of Pharmacy/University of Pittsburgh Medical Center-Presbyterian Hospital. P4 PharmD Candidates. Co-Preceptor (5 days for 4 weeks) Fall 2010.

APPE Drug Information Rotation. St. Vincent's Medical Center/University of Florida College of Pharmacy. P4 PharmD Candidate. Co-Preceptor (5 days for 4 weeks) Winter 2009.

APPE Infectious Diseases Rotation. St. Vincent's Medical Center/Florida Agricultural and Mechanical University College of Pharmacy and Pharmaceutical Sciences. P4 PharmD Candidate. Co-Preceptor (5 days for 4 weeks) Fall 2009.

Pharmaceuticals Skills Laboratory (PHA 5108L). University of Florida College of Pharmacy. P3 PharmD Candidates. Facilitator. Fall 2009.

Platform Presentations

Achieving Optimal Health Outcomes through Outpatient Antimicrobial Stewardship 2017
Presented CE to Pharmacists & Technicians at regional Maine Society Health-System Pharmacists
UAN# 0837-9999-17-038-L01-P/T

Antimicrobial Stewardship: Advancing Patient Care by Improving Medication Use 2017
Presented CE to Pharmacists & Technicians at regional Maine Pharmacy Association
UAN# 0837-9999-17-030-L01-P/T

The Rise of Antimicrobial Resistance and Antimicrobial Stewardship 2016
Presented CE to Pharmacists, Physicians, Nurses, Technicians at regional Maine CDC

Age of New Antimicrobials: Novelty versus Imitation 2015
Presented CE credit to Pharmacists, Pharmacy students and technicians at regional MSHP
UAN#0837-9999-15-137-LO1-P/T

Clinician's Guide to Optimizing Beta-Lactams through Extended Infusion 2011
Presented CE credit to Pharmacists and Pharmacy technicians

Drug Therapy Management of Clostridium difficile- Associated Diarrhea. Guideline Protocol and Order Set. 2011
Presented to Pharmacy and Therapeutics Committee.

In vitro Susceptibilities of Fosfomycin against Enterobacteriaceae Producing KPC- Type Beta-Lactamases 2011
Presented to ID grand rounds to ID physicians, fellows, medical residents
Presented to clinical pharmacists, preceptors, and pharmacy students

Novel Daptomycin Combination against Daptomycin-Nonsusceptible Methicillin Resistant Staphylococcus aureus. Journal Club. 2011
Presented to ID physicians, preceptors, fellows, and medical residents

Impact of Early Oseltamivir Treatment on Outcome in Critically ill Patients with 2009 Pandemic Influenza A. Journal Club. 2011
Presented to clinical pharmacists, preceptors, pharmacy residents and students

Principles of Antibiotics 2011
Monthly lecture presented to medical residents and students at UPMC

Rapid Identification for Methicillin-Resistant Staphylococcal aureus Bacteremia. ID Grand Rounds Puzzler. 2011
Presented to ID physicians, fellows, medical residents and students

<i>Therapeutic Drug Monitoring of Linezolid. Journal Club.</i>	2010
Presented to clinical pharmacists, preceptors, pharmacy residents and students	
<i>Infective Endocarditis: Adjunctive Use of Ceftriaxone for the Treatment of Enterococcus Faecalis</i>	2010
Presented to pharmacy residents, preceptors, students and faculty	
<i>Bugs & Drugs: The Rise of Gram Negative Bacteria</i>	2010
UAN: 0077-9999-10-014-L01-P; UPN: 0012-0000-10-074-H01-P	
Presented CE credit to physicians, pharmacists, nurses, and medical technologists	
<i>Urinary Tract Infections in the Community Setting</i>	2010
Presented to medical residents and attending physicians	
<i>Preventative Medicine and Health Maintenance</i>	2010
Presented to pharmacy residents, preceptors, students and faculty	
<i>Carbapenem MUE and Drug Class Review</i>	2010
Presented to pharmacy and therapeutics committee and medical executive committee	
<i>Human Papillomavirus Virus Update</i>	2010
Presented to pharmacy residents, preceptors, students and faculty	
<i>Proper Use of Antibiotics In-Service</i>	2009
Presented to family medicine residents and physicians	
<i>Clinical Trial Jeopardy</i>	2009
Presented to pharmacy residents, preceptors, students and faculty	
<i>Cold and Cough Evidence Base Medicine Review</i>	2009
Presented to pharmacy residents, preceptors, students and medical residents	
<i>Drug Induced Nephrotoxicity</i>	2009
Presented to pharmacy residents, preceptors, students and faculty	
<i>Beta-Lactam Dose Optimization in Critical Care Units In-Service</i>	2009
Presented to pharmacists, physicians and nurses at St. Vincent's Medical Center	
<i>Microsoft Excel and Data Collection</i>	2009
Presented to pharmacy residents, preceptors, students and faculty	
<i>Prerenal Nephrotoxicity</i>	2009
Presented to pharmacy residents, preceptors, students and faculty	
<i>Dronedarone In-Service</i>	2009
Presented to nurses at St. Vincent's Medical Center	
<i>Update on H1N1 2009</i>	2009
Presented to pharmacy residents, preceptors, students and faculty	

Case Presentation: Septic Arthritis 2009
Presented to pharmacy residents, preceptors, students and faculty

Leadership Activities

Associate Editor March 2017–Present
Harvard Public Health Review

American Pharmacists Association Advisor February 2017–Present
Husson University School of Pharmacy

HAI Collaborating Partners Committee July 2015–Present
Maine Center for Disease Control and Prevention

Medication Management Committee September 2014–Present
Eastern Maine Health System

Antimicrobial Stewardship Committee September 2014–Present
Eastern Maine Medical Center

Infection Prevention and Control Function Team
Eastern Maine Medical Center September 2014–Present

Assessment Committee August 2014–May 2016
Husson University School of Pharmacy

Internet Committee September 2014– August 2015
Society of Infectious Diseases Pharmacists (SIDP)

Recognition Awards Committee September 2012– August 2014
Society of Infectious Diseases Pharmacists (SIDP)

Interorganizational Committee September 2011– August 2012
Society of Infectious Diseases Pharmacists (SIDP)

Organization Affairs Council 2009 – 2010
Florida Society of Health-System Pharmacists (FSHP)
Establish a plan for membership development and retention including special membership benefits and promotions to target groups. Organize the FSHP Professional Policy and Procedure Manual.

Electronic Mentor 2009 – Present
Wingate University School of Pharmacy
Respond to questions specific to practice, interests and passions while allowing first year pharmacy students to learn from the insight and real-world experiences of multiple mentors.

Student Forum Membership Advisory Group 2007 – 2008
National Student Forum of ASHP
Promoted student membership by highlighting the value of ASHP. Evaluated current student member benefits and services. Promoted careers in health-system pharmacy and disseminated health system information

ASHP-Student Society President 2007 – 2008
Wingate University School of Pharmacy

Professionalization Committee Student Representative 2007 – 2008
Wingate University School of Pharmacy
Deliberated on student honors and awards and developed an annual special activity calendar of professional opportunities.

ASHP-Student Society Liaison 2005 – 2007
Wingate University School of Pharmacy
Promoted involvement in professional service activities to enhance student professionalism and support the university and community.

Class Treasurer 2003 – 2004
Midwestern University College of Health Science
Initiated fundraisers to assist professionalism and budgeted Midwestern University Biomedical Science Program funds.

Professional Associations

American Association of Colleges of Pharmacy (AACP)	August 2014 – Present
European Society of Clinical Microbiology and Infectious Diseases	October 2012 – Present
Society of Infectious Diseases of Infectious Diseases of Pharmacists (SIDP)	Sept 2011 – Present
Infectious Diseases Society of America (IDSA)	October 2011 – Present
American Society for Microbiology (ASM)	August 2011 – Present
American College of Clinical Pharmacy (ACCP)	2005 – 2013
Pennsylvania Society of Health-System Pharmacist (PSHP)	2010 – 2011
American Society of Health-System Pharmacist (ASHP)	2005 – 2010
Florida Society of Health-System Pharmacist (FSHP)	2009 – 2010
North Carolina Association of Pharmacists (NCAP)	2005 – 2009
American Pharmacists Association (APhA)	2005 – 2008

Funded Research Grants

Casapao AM. Primary Investigator. Impact of Delaying Antibiotic Prescriptions for Patients with Chronic Obstructive Pulmonary Disease: Antimicrobial Stewardship Initiative. NACDS Foundation. Proposal submitted and Funding denied.

Casapao AM. Co-Investigator. Development and Implementation of Intramural Comprehensive Examination for P2s. Intramural Husson University School of Pharmacy. (\$3,825 01/01/2017-12/31/2017).

Casapao AM. Co-Investigator. Pharmacoepidemiology of Antimicrobial Therapy Optimization in Patients with Escherichia coli Bloodstream Infection. Intramural Husson University School of Pharmacy. (\$3,500 07/01/2016-06/30/2016).

Casapao AM. Co-Investigator. Oritavancin Assay Development continuation. Intramural Husson University School of Pharmacy. (\$3,000 07/01/2016-06/30/2016).

Casapao AM. Co-Investigator. Oritavancin Assay Development Pilot Study. Intramural Husson University School of Pharmacy. (\$4,000 07/01/2015-06/30/2016).

Casapao AM. Co-Investigator. Characterization of the Treatment of Candiduria. Astellas Pharma US, Inc. (\$62,614 01/01/2015-12/31/2015).

Casapao AM. Principal Investigator. Ten Year Epidemiology Report of *Staphylococcus aureus* Infections in State of Maine. American Association of Colleges of Pharmacy. Protocol submitted and Funding denied.

Casapao AM. Principal Investigator. Impact of Early Beta-Lactam Therapy in Combination with Standard Therapy for Methicillin-Resistant *Staphylococcus aureus* Bloodstream Infections. Intramural Husson University School of Pharmacy. (\$8,000 07/01/2014-06/30/2016).

Casapao AM. Co-Investigator. Patient Outcomes Burden of Illness with Lower Respiratory Infections in Intensive Care Units. Cubist Pharmaceuticals Inc. (\$151,996 08/01/2014-07/31/2016).

Casapao AM. Co-Investigator. Cost-Analysis of Rapid Identification with Nanosphere Verigene Blood Culture Assay in Patients with Suspected Gram-Positive Bacteremia. Nanosphere. Protocol submitted and Funding denied.

Casapao AM. Co-Investigator. Impact of Early Daptomycin versus Vancomycin Therapy for Bloodstream Infection Caused by Methicillin-Resistant *Staphylococcus aureus*. Cubist Pharmaceuticals Inc. (\$177,792.50 02/01/2013-02/01/2015)

Casapao AM. Co-Investigator. A Retrospective, Comparative Evaluation of Acute Bacterial Skin and Skin Structure Infections Receiving Ceftaroline or Vancomycin. Forest Research Institute. Protocol submitted and Funding denied.

Casapao AM. Co-Investigator. Clinical and Economic Outcomes of Ceftaroline Fosamil for the Treatment of Acute Bacterial Skin and Skin Structure Infections with Documented or at Risk of Methicillin-Resistant *Staphylococcus aureus*. Forest Research Institute. (\$254,310.00 04/01/2012-04/30/2014)

Casapao AM. Co-Investigator. Antimicrobial Use and Resistance (AUR) Option. National Healthcare Safety Network (NHSN) and Michigan Department of Community Health (MDCH). (\$223,491.24 08/01/2011-07/31/2013)

Casapao AM. Co-Investigator. High-Dose Daptomycin for Enterococcal Infections; A multi-center evaluation. Cubist Pharmaceuticals. (\$134,750.00 6/01/10-10/31/12)

Honors and Awards

Williams F. Beardsley Teaching Excellence Award – Husson University	2017
P4 Teacher of the Year – Husson University School of Pharmacy	2017
Distinguished Research Award – Husson University	2016
Intramural Husson University School of Pharmacy Research Grant	2014/2015/2016/2017
24 th ECCMID Travel Grant	2014
16 th MAD-ID Travel Grant	2013
23 rd ECCMID Travel Grant	2013
52 nd ICAAC Post-Doctoral Travel Grant	2012
15 th MAD-ID Travel Grant	2012
51 st ICAAC ID Fellows Grant	2011
Cum Laude, Wingate University School of Pharmacy	2009

Inducted into Phi Lambda Sigma 2007
Magna Cum Laude, Midwestern University 2005

Licensures and Certifications

Registered Pharmacist, State of Florida Board of Pharmacy 2009 – Present
Registered Pharmacist, Commonwealth of Pennsylvania State Board of Pharmacy 2011– Present
Registered Pharmacist, State of Maine Board of Pharmacy 2014 – Present
Advance Cardiac Life Support – Certified Provider 2009 – 2012
Basic Life Support – Certified Provider 2009 – Present

References are available upon request